Showing 4061-4070 of 5957 results for "".
- Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meetinghttps://modernod.com/news/nicox-announces-presentation-of-data-on-ncx-470-at-the-2024-american-glaucoma-society-annual-meeting/2482143/Nicox SA provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) annual meeting, one of the key scientific events in vision research, which was held February 29-March 3, 2024, in Huntington Beach, California. Poster tit
- Study: Blindness from Some Inherited Eye Diseases May be Caused by Gut Bacteriahttps://modernod.com/news/study-blindness-from-some-inherited-eye-diseases-may-be-caused-by-gut-bacteria/2482140/Sight loss in certain inherited eye diseases may be caused by gut bacteria, and is potentially treatable by antimicrobials, according to a new study in mice co-led by a University College London (UCL) and Moorf
- Palitin Misses Co-Primary Endpoints in Phase 3 Dry Eye Disease Trialhttps://modernod.com/news/palitin-misses-co-primary-endpoints-in-phase-3-trial-dry-eye-disease-candidate/2482136/Palatin Technologies did not achieve statistical significance in the co-primary endpoints of its pivotal phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED). MELODY-1 had two co-primary efficacy endpoints
- Swiss Advanced Vision Launches New Features for its Toric Calculatorhttps://modernod.com/news/swiss-advanced-vision-launches-new-features-for-its-toric-calculator/2482130/Swiss Advanced Vision (SAV-IOL) announced the launch of new features for its toric calculator designed to improve the calculation experience. For the first-time, ophthalmologists will be able to use a web-based configurator to help define the best incision location to minimize resi
- Alcon to Unveil Updated MARLO App at SECO 2024https://modernod.com/news/alcon-to-unveil-new-marlo-app-at-seco-2024/2482127/Alcon announced it will showcase the new MARLO App at the SECO International meeting in Atlanta. The app includes new features for patients and is now available to download in the Apple App Store. Launched in 2020, MARLO was developed as an online platform to h
- Eversight Partners with Emmecell Biotech to Advance Ocular Cell Therapieshttps://modernod.com/news/eversight-partners-with-emmecell-biotech-to-advance-ocular-cell-therapies/2482124/Global nonprofit eye bank Eversight has partnered with biotech company Emmecell to advance cell therapies for the treatment of eye disease. Financial terms of the deal were not disclosed. Emmecell’s minimally invasive cell therapy injects healthy corneal
- RetinAI Launches Discovery Platform for Ophthalmology and Optometry Clinicshttps://modernod.com/news/retinai-discovery-platform-launched-to-improve-workflows-referrals-and-patient-management-in-ophthalmology-and-optometry-clinics/2482122/Ikerian, the parent company of RetinAI, announced the launch of 'RetinAI Discovery for Clinics,' which features AI models designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient manage
- Johnson & Johnson Launches Tecnis PureSee Presbyopia-Correcting IOL in EMEAhttps://modernod.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/Johnson & Johnson MedTech announced that its Tecnis PureSee presbyopia-correcting IOL is now available in Europe, the Middle East, and Africa (EMEA). The Tecnis PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-cat
- Ocular Therapeutix Announces First Subjects Screened in Phase 3 Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degenerati
- EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restorethttps://modernod.com/news/eyebio-announces-positive-visual-anatomic-and-safety-data-from-first-in-human-ph1b2a-amarone-trial-of-restoret/2482112/Eyebiotech announced the presentation of Week 12 data from its first-in-human phase 1b/2a AMARONE trial of Restoret in patients with treatment-naïve diabetic macular edema (DME) and treatment-naïve wet age-related macular degeneration (AMD). The analysis was presented by Charles C.